Trial Profile

Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Aspirin
Indications Coronary artery disease; Peripheral arterial disorders
Focus Biomarker; Therapeutic Use

Most Recent Events

13 Nov 2023 Results (n=9) assessing synergistic influence of rivaroxaban on platelets, inflammation and coagulation biomarkers, presented at the American Heart Association Scientific Sessions 2023.
12 Oct 2020 Planned End Date changed from 1 Mar 2020 to 1 Aug 2021.
12 Oct 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Mar 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com